FDA OTC Monograph — Cold, Cough, Allergy, and Antiasthmatic Drug Products

Walk down any drugstore cold-and-flu aisle and you'll find hundreds of products — NyQuil, Robitussin, Sudafed, Mucinex, Claritin, Primatene Mist — bearing Drug Facts panels that list a small set of familiar active ingredients. That familiarity is not accidental. 21 CFR Part 341 is the FDA's over-the-counter monograph for cold, cough, allergy, bronchodilator, and antiasthmatic drug products: it specifies exactly which active ingredients are approved, at what doses, in which forms, and with which labeling language a product must use to be marketed without a prescription and without an individual FDA premarket approval. A product that follows Part 341 is Generally Recognized as Safe and Effective (GRASE) for OTC use. One that doesn't requires a New Drug Application.

Legal Authority

• 21 U.S.C. § 355 — FDCA § 505: New drug approval requirement; OTC drug monographs provide an alternative to individual NDAs for products that comply with monograph specifications — compliance with the monograph is deemed FDA approval for GRASE ingredients
• 21 U.S.C. § 321 — FDCA definitions: defines "drug" to include articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease; OTC cold/cough products are drugs subject to FDCA
• 21 CFR Part 341 — FDA OTC monograph for cold, cough, allergy, bronchodilator, and antiasthmatic drug products; specifies GRASE active ingredients, dose ranges, permitted combinations, labeling requirements, and product classification

Key Mechanics

The OTC monograph system functions as a standing authorization: a cold medicine manufacturer who formulates a product within Part 341's specifications — using approved active ingredients at approved concentrations, with the required Drug Facts label — can market the product without filing an individual NDA. The OTC Monograph Reform Act of 2020 (part of the CARES Act) overhauled the monograph system: monographs are now finalized as administrative orders rather than rules, and can be updated more quickly through an expedited process. Under the reformed system, the phenylephrine controversy — extensive evidence that oral phenylephrine (the most common decongestant in OTC cold products) may not be effective at approved doses — led the FDA's Nonprescription Drug Advisory Committee to recommend in September 2023 that oral phenylephrine be removed from the GRASE category; the rulemaking to update the monograph was ongoing as of 2026.

Current Rule (2026)

What This Rule Does

Part 341 defines which active ingredients, at which concentrations, in which dosage forms, may lawfully be sold as OTC cold and allergy products. Before the OTC monograph system existed, manufacturers had to file individual New Drug Applications for each product — an impossibly burdensome process for the thousands of cold and cough formulations on the market. The monograph system, developed through the 1970s–1990s, created a standardized approval framework: meet the monograph conditions, use the required labeling language, and your product is legally marketable as an OTC drug without individual FDA review.

The CARES Act of 2020 modernized the legal framework for OTC monographs. Conditions established in regulations like Part 341 were converted into administrative orders — a legal form that FDA can update through a streamlined process without full notice-and-comment rulemaking. For manufacturers, the practical effect is that existing Part 341 conditions remain valid, but FDA can now update the approved ingredient list, doses, or labeling requirements faster than before. Check the FDA OTC Monographs database for the current status of each ingredient.

Part 341 covers five distinct drug categories, each with its own approved ingredients and labeling requirements.

Key Provisions

Subpart B — Antihistamines (§§ 341.12, 341.72)

• § 341.12 — Approved antihistamine ingredients: Part 341 lists approximately 14 antihistamine active ingredients approved for OTC allergy relief, including brompheniramine maleate, chlorpheniramine maleate, dexbrompheniramine maleate, diphenhydramine hydrochloride, diphenhydramine citrate, doxylamine succinate, loratadine, and several others — each approved only within specific dosage ranges and dosage forms; loratadine (Claritin) is notable as a non-sedating antihistamine approved at 10 mg for adults (and weight-based doses for children); diphenhydramine (Benadryl) is the most widely used, approved for both allergy relief and OTC sleep aid labeling
• § 341.72 — Antihistamine labeling: the Drug Facts panel must identify the product as an "antihistamine"; approved indications include runny nose, sneezing, itchy/watery eyes, and itching of the nose or throat; required warnings must address: drowsiness (for sedating antihistamines), alcohol interaction (increases drowsiness), use caution driving or operating heavy machinery; labeling must warn against use by persons with glaucoma or enlarged prostate without physician guidance, as antihistamines' anticholinergic effects can worsen both conditions

Subpart C — Antitussives (§§ 341.14, 341.74)

• § 341.14 — Approved antitussive ingredients: two primary OTC antitussive categories:
  • Oral antitussives: dextromethorphan hydrobromide (the dominant OTC cough suppressant — Robitussin DM, Delsym, Vicks 44) approved at 10–20 mg per dose every 4 hours for adults; dextromethorphan polistirex (extended-release formulation); chlophedianol hydrochloride (less common); codeine and codeine phosphate (retained as OTC antitussives in limited concentrations — OTC codeine status varies by state, with several states restricting OTC codeine sales to behind-the-counter)
  • Topical/antitussive application (§ 341.74(d)): camphor 4.7–5.3 percent in appropriate base and menthol 2.6–2.8 percent in appropriate base are approved as topical cough suppressants (the active ingredients in Vicks VapoRub) — applied to the chest and throat, the vapors are inhaled and suppress cough through a sensory mechanism distinct from systemic antitussives
• § 341.74 — Antitussive labeling: Drug Facts must identify the product as a "cough suppressant" or "antitussive (cough suppressant)"; indication must state relief of coughs due to minor throat and bronchial irritation; warnings must caution against use for persistent cough, cough accompanying asthma or emphysema, or cough with excessive phlegm without physician guidance

Subpart D — Bronchodilators (§§ 341.16, 341.76)

• § 341.16 — Approved bronchodilator ingredients: OTC bronchodilators for asthma symptom relief are the most tightly regulated category in Part 341, reflecting the serious nature of asthma:
  • Epinephrine and epinephrine bitartrate (in inhalation aerosol form — Primatene Mist): the only approved OTC bronchodilator for inhalation; the product delivers 0.22 mg epinephrine per actuation; approved for "temporary relief of mild symptoms of intermittent asthma"; a significant 2008–2018 gap occurred when the original Primatene Mist was withdrawn due to its CFC propellant (banned under the Montreal Protocol) — the product returned in 2018 as Primatene Mist HFA using a non-CFC propellant
  • Ephedrine, ephedrine hydrochloride, and ephedrine sulfate (in oral form): approved at 12.5–25 mg per dose every 4 hours for adults; ephedrine's regulatory status is complex — the Combat Methamphetamine Epidemic Act of 2005 (CMEA) requires ephedrine-containing products to be sold behind the pharmacy counter with purchase quantity limits and purchaser ID, even though they remain OTC drugs under Part 341; this creates the anomalous situation of a product that is legally OTC but cannot be placed on an open shelf
• § 341.76 — Bronchodilator labeling: the indication must state "for temporary relief of mild symptoms of intermittent asthma"; required warnings are extensive and safety-critical: "if you are not sure if you have asthma, ask a doctor before use"; "do not use more often or at higher doses than recommended"; "avoid use if you have heart disease, high blood pressure, thyroid disease, diabetes, or difficulty urinating"; the labeling must instruct users to consult a physician if symptoms do not improve within one hour or worsen

Subpart E — Expectorant (§§ 341.18, 341.78)

• § 341.18 — The only approved expectorant: guaifenesin (glyceryl guaiacolate) is the sole OTC expectorant ingredient approved in Part 341, at 100–400 mg per dose every 4 hours; the mechanism is believed to involve thinning and loosening of mucus in the bronchial passageways, making coughs more productive; Mucinex (guaifenesin 600 mg extended-release) operates under Part 341 at the maximum approved dose; guaifenesin's evidence base for clinical efficacy has been debated — the benefit is modest but the risk profile is extremely low, justifying OTC availability
• § 341.78 — Expectorant labeling: "expectorant" is the required statement of identity; indication must state "helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive"; warnings must caution against use if cough is associated with asthma, emphysema, or excessive secretions

Subpart F — Nasal Decongestants (§§ 341.20, 341.80)

• § 341.20 — Approved nasal decongestant ingredients: two delivery route categories:
  • Oral decongestants: phenylephrine hydrochloride (10 mg per dose every 4 hours — common in products marketed as Sudafed PE after pseudoephedrine was moved behind the counter) and pseudoephedrine hydrochloride / pseudoephedrine sulfate (30–60 mg per dose every 4–6 hours — Sudafed original); pseudoephedrine's OTC status is preserved under Part 341 but CMEA requires behind-the-counter placement, purchaser age verification, ID recording, and daily/monthly purchase quantity limits at the federal level (with stricter limits in some states); phenylephrine's OTC status is under FDA re-evaluation after a September 2023 FDA advisory committee voted unanimously that oral phenylephrine is not effective as a nasal decongestant at the approved OTC dose — FDA issued a proposed order to remove oral phenylephrine from the OTC monograph in 2024, which would remove PE-branded products from shelves absent reformulation or NDA approval
  • Topical nasal decongestants: oxymetazoline hydrochloride 0.05 percent (Afrin) — spray or drops, limited to 3 consecutive days of use to prevent rebound congestion (rhinitis medicamentosa); xylometazoline hydrochloride 0.1 percent (adult) and 0.05 percent (pediatric); phenylephrine hydrochloride in topical nasal formulations (0.125–1 percent depending on age group)
• § 341.80 — Nasal decongestant labeling: must identify product as "nasal decongestant"; approved indication is "temporarily relieves nasal congestion due to the common cold, hay fever, or other upper respiratory allergies"; topical decongestant labeling must include the "do not use for more than 3 days" warning and caution that overuse may cause nasal congestion to recur or worsen

Subpart G — Combinations and Multi-Symptom Products (§§ 341.40, 341.85)

• § 341.40 — Permitted combinations: the vast majority of cold and flu products on the market are multi-symptom formulas combining ingredients from the five categories; Part 341 permits specific combinations provided each ingredient is within its individual dose range — permitted combinations include: any antihistamine + any antitussive; antihistamine + nasal decongestant; antitussive + expectorant; antitussive + nasal decongestant; antihistamine + antitussive + nasal decongestant; expectorant + nasal decongestant; among others; acetaminophen and NSAIDs from other monographs (Parts 343, 356) may also be combined with Part 341 ingredients
• § 341.85 — Combination labeling: the Drug Facts indications, warnings, and directions for each active ingredient may be combined to eliminate redundancy, provided the combined statement remains accurate and complete for each ingredient; the required warnings for all ingredients must appear regardless of the labeling consolidation

How It Affects You

If you are a consumer: the active ingredients on a cold product's Drug Facts panel tell you exactly what the product does — and what it doesn't. For symptom-specific selection: an antihistamine addresses runny nose and sneezing; a decongestant addresses nasal congestion (but oral phenylephrine may not be effective — watch for FDA's potential order removing it from shelves); guaifenesin loosens mucus; dextromethorphan suppresses cough; ephedrine or inhaled epinephrine provides bronchodilation for mild asthma. Multi-symptom products include ingredients you may not need — a person with a dry cough and congestion does not need an antihistamine or expectorant. Oral pseudoephedrine is typically more effective than phenylephrine as a decongestant but requires showing ID at the pharmacy counter.

If you manufacture or plan to market OTC cold and allergy products: complying with Part 341 requires matching every element — active ingredient identity, concentration, dosage form, and Drug Facts labeling language — to the monograph conditions. A product containing an active ingredient not listed in Part 341, or at a concentration outside the approved range, cannot claim GRASE status and requires an approved NDA or NDA supplement before marketing. Under the CARES Act, FDA can now issue administrative orders to add, modify, or remove ingredients from the OTC monograph more quickly than through notice-and-comment rulemaking. The ongoing FDA re-evaluation of oral phenylephrine's effectiveness illustrates this: manufacturers who built product lines around PE-formulations are facing potential removal of that ingredient from the approved monograph, requiring reformulation or a product-specific NDA.

If you are a pharmacist: counseling points for common Part 341 drugs: (1) pseudoephedrine remains more effective than phenylephrine as an oral decongestant for most patients, and the behind-the-counter inconvenience is worth it for patients with significant congestion; (2) oxymetazoline (Afrin) is highly effective for nasal congestion but strictly limited to 3 days — longer use causes rebound congestion that becomes worse than the original congestion; (3) antihistamine choice matters — sedating first-generation antihistamines (diphenhydramine, doxylamine) cause more drowsiness and cognitive impairment than loratadine; (4) dextromethorphan at high doses carries abuse potential (particularly among teenagers) — several states have enacted age restrictions on DXM-containing products.

Statutory Authority

This rule implements:

• 21 U.S.C. § 355 — New drug approval requirements; OTC monograph products meeting Part 341 conditions are exempt from individual NDA review
• 21 U.S.C. § 321(p) — Definition of "new drug" and the GRASE standard; products meeting monograph conditions are not "new drugs" requiring NDA approval
• 21 U.S.C. § 352 — Misbranding provisions; products not meeting Part 341 labeling requirements are misbranded
• 21 U.S.C. §§ 360fff–360fff-8 — OTC Drug Monograph Reform (CARES Act of 2020, Title III): converted OTC monograph conditions from regulations into administrative orders; authorized expedited FDA order process for modifying monograph conditions

Recent Rulemakings

• CARES Act of 2020 (Pub. L. 116-136, Title III) — OTC Drug Monograph Reform: enacted the administrative order mechanism replacing notice-and-comment rulemaking for OTC monograph updates; existing Part 341 conditions deemed final orders under the new framework
• Combat Methamphetamine Epidemic Act of 2005 (CMEA) — not an FDA rulemaking but a Congressional statute that created behind-the-counter requirements for pseudoephedrine and ephedrine — the major sales-channel change affecting Part 341 products
• 2018 — Primatene Mist HFA reintroduction: FDA allowed reintroduction of the only OTC epinephrine inhaler with a non-CFC HFA propellant (hydrofluoroalkane), restoring OTC bronchodilator access for mild asthma patients; the original CFC-propelled Primatene Mist was withdrawn in 2011 under the Montreal Protocol-driven CFC phaseout
• 2024 FDA proposed order on oral phenylephrine: after a September 2023 advisory committee voted unanimously that oral phenylephrine is not effective as an OTC nasal decongestant at approved doses, FDA issued a proposed administrative order on November 7, 2024 (OTC000036) to remove oral phenylephrine from the OTC monograph; the comment period closed May 7, 2025; as of May 2026 the order has not been finalized; if finalized, oral PE products would require reformulation or an NDA; topical phenylephrine (nasal sprays/drops) is not affected by the proposed order and would remain on the approved monograph

Pending Action